Laboratory of Parasitology, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
PLoS Negl Trop Dis. 2012;6(8):e1798. doi: 10.1371/journal.pntd.0001798. Epub 2012 Aug 21.
Visceral leishmaniasis (VL) is a chronic and fatal disease in humans and dogs caused by the intracellular protozoan parasites, Leishmania donovani and L. infantum (L. chagasi). Relapse of disease is frequent in immunocompromised patients, in which the number of VL cases has been increasing recently. The present study is aimed to improve the understanding of mechanisms of L. donovani persistence in immunocompromised conditions using alymphoplastic aly/aly mice. Hepatic parasite burden, granuloma formation and induction of regulatory T cells were determined for up to 7 months after the intravenous inoculation with L. donovani promastigotes. While control aly/+ mice showed a peak of hepatic parasite growth at 4 weeks post infection (WPI) and resolved the infection by 8 WPI, aly/aly mice showed a similar peak in hepatic parasite burden but maintained persistent in the chronic phase of infection, which was associated with delayed and impaired granuloma maturation. Although hepatic CD4(+)Foxp3(+) but not CD8(+)Foxp3(+) T cells were first detected at 4 WPI in both strains of mice, the number of CD4(+)Foxp3(+) T cells was significantly increased in aly/aly mice from 8 WPI. Immunohistochemical analysis demonstrated the presence of Foxp3(+) T cells in L. donovani-induced hepatic granulomas and perivascular neo-lymphoid aggregates. Quantitative real-time PCR analysis of mature granulomas collected by laser microdissection revealed the correlation of Foxp3 and IL-10 mRNA level. Furthermore, treatment of infected aly/aly mice with anti-CD25 or anti-FR4 mAb resulted in significant reductions in both hepatic Foxp3(+) cells and parasite burden. Thus, we provide the first evidence that CD4(+)Foxp3(+) Tregs mediate L. donovani persistence in the liver during VL in immunodeficient murine model, a result that will help to establish new strategies of immunotherapy against this intracellular protozoan pathogen.
内脏利什曼病(VL)是一种由细胞内原生动物寄生虫利什曼原虫和 L. infantum(L. chagasi)引起的人类和犬类的慢性和致命疾病。免疫功能低下的患者中疾病复发频繁,最近 VL 病例数量一直在增加。本研究旨在使用无淋巴形成的 aly/aly 小鼠来提高对利什曼原虫在免疫功能低下条件下持续存在机制的理解。在用 L. donovani 前鞭毛体静脉接种后,最多 7 个月测定肝寄生虫负担、肉芽肿形成和诱导调节性 T 细胞。虽然对照 aly/+ 小鼠在感染后 4 周(WPI)时显示肝寄生虫生长的峰值,并在 8 WPI 时消除感染,但 aly/aly 小鼠显示出相似的肝寄生虫负担峰值,但在感染的慢性期保持持续存在,这与肉芽肿成熟延迟和受损有关。尽管在两种小鼠品系中,肝 CD4(+)Foxp3(+)但不是 CD8(+)Foxp3(+)T 细胞在 4 WPI 时首先被检测到,但从 8 WPI 开始,aly/aly 小鼠中 CD4(+)Foxp3(+)T 细胞的数量显著增加。免疫组织化学分析表明,Foxp3(+)T 细胞存在于 L. donovani 诱导的肝肉芽肿和血管周围新淋巴样聚集物中。通过激光微切割收集的成熟肉芽肿的定量实时 PCR 分析显示 Foxp3 和 IL-10 mRNA 水平的相关性。此外,用抗 CD25 或抗 FR4 mAb 治疗感染的 aly/aly 小鼠可显著减少肝 Foxp3(+)细胞和寄生虫负担。因此,我们首次提供了证据表明 CD4(+)Foxp3(+)Treg 在免疫缺陷小鼠模型中在 VL 期间介导利什曼原虫在肝脏中的持续存在,这一结果将有助于建立针对这种细胞内原生动物病原体的新免疫治疗策略。